Understanding Epilepsy in Pregnancy Outcomes

Managing epilepsy in pregnancy outcomes presents a significant challenge for neurologists and obstetricians. Recent evidence from the Raoul Wallenberg Australian Register of Antiepileptic Drugs suggests that the history of a woman's initial pregnancy can offer vital clues for her subsequent ones. Clinicians must balance the need for seizure control with the potential teratogenic effects of antiseizure medications (ASMs).

The study analyzed consecutive pregnancies to determine how seizure frequency and fetal malformation rates evolve over time. Interestingly, researchers found that the management of the first pregnancy often sets the stage for the second. Consequently, understanding these patterns helps in optimizing preconception counseling for women of childbearing age in India and globally.

Key Findings for Epilepsy in Pregnancy Outcomes

The data revealed that seizure freedom rates throughout pregnancy were actually higher in the subsequent pregnancy compared to the initial one. Specifically, seizure freedom rose from 52.9% to 60.8%. This improvement was most pronounced when the ASM therapy remained unchanged between the two pregnancies. This suggests that stable medication regimens contribute significantly to better maternal health in later gestations.

However, the findings regarding fetal malformations require a more cautious interpretation. While the overall occurrence rates remained similar across pregnancies, the risk profile varied by epilepsy type. Women with generalized epilepsy faced a higher risk of malformations compared to those with focal epilepsies. Specifically, the recurrence rate for a malformed baby was notably higher in women with generalized epilepsy who had already experienced a malformation in a previous pregnancy.

Clinical Implications for Subsequent Pregnancies

For women with generalized epilepsy and a history of fetal malformation, the risk of a second malformed baby reached 50%. In contrast, this risk was only 7.7% for women with focal epilepsy. This disparity highlights the need for specialized monitoring and potentially different ASM strategies for those with generalized syndromes. Furthermore, folic acid supplementation remains a cornerstone of preconception care, particularly in regions like India where nutritional variances occur.

Medical professionals should emphasize that while seizure control often improves, the structural risks to the fetus depend heavily on the underlying epilepsy type and previous history. Therefore, detailed counseling should focus on these individualized risk factors before a woman conceives her second child. Additionally, maintaining the same effective ASM, if possible, seems to support the trend toward better seizure freedom in later pregnancies.

Frequently Asked Questions

Does seizure control improve in a second pregnancy?

Yes, research indicates that seizure freedom rates are generally higher in subsequent pregnancies, especially when the antiseizure medication remains consistent. This may be due to better clinical management and patient adherence following the first experience.

What is the recurrence risk of fetal malformations in women with epilepsy?

The risk is significantly higher for women with generalized epilepsy who have previously had a malformed baby. In this group, the recurrence risk can be as high as 50%, whereas it is much lower for those with focal epilepsy.

Should ASMs be changed between pregnancies?

Stability is often preferred. The data suggests that keeping the same ASM therapy leads to higher rates of seizure freedom in the next pregnancy. However, if a malformation occurred, a thorough review of the medication type and dosage by a specialist is mandatory.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Vajda F et al. The outcomes of consecutive pregnancies in Australian women with epilepsy. Epileptic Disord. 2026 May 15. doi: 10.1002/epd2.70265. PMID: 42138059.

Battino D et al. Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy. JAMA Neurol. 2024;81(4):352-360.

FOGSI Medical Disorders in Pregnancy Committee. Guidelines on Epilepsy in Pregnancy. Obstetric and Gynecological Societies of India.